EUCTR2006-000995-33-PL进行中（未招募）1 期
EuroNet-Paediatric Hodgkin’s Lymphoma Group First international Inter-Group Studyfor classical Hodgkin’s Lymphoma in Children and Adolescents - EuroNet-PHL-C1
Martin-Luther-University Halle-Wittenberg0 个研究点目标入组 1,200 人开始时间: 2010年1月19日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 1,200
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •diagnosis of classic Hodgkin’s lymphoma
- •patient aged under 18 years at time of diagnosis
- •written informed consent of the patient and/or the patient’s parents or guardian according to national laws
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •pre-treatment of Hodgkin’s lymphoma differing from study protocol (except recommended pre-phase therapy of a large mediastinal tumour)
- •known hypersensitivity or contraindication to study drugs
- •diagnosis of lymphocyte predominant Hodgkin’s lymphoma
- •prior chemotherapy or radiotherapy
- •other (simultaneous) malignancies
- •pregnancy and / or lactation
- •females who are sexually active refusing to use effective contraception (oral contraception, intrauterine devices, barrier method of contraception in conjunction with spermicidal jelly or surgical sterile)
- •Current or recent (within 30 days prior to start of trial treatment) treatment with another investigational drug or participation in another investigational trial
- •severe concomitant diseases (e.g. immune deficiency syndrome)
- •known HIV positivity
研究者
相似试验
进行中（未招募）
1 期
EuroNet-Paediatric Hodgkin’s Lymphoma Group First international Inter-Group Studyfor nodular lymphocyte-predominant Hodgkin’s Lymphoma in Children and Adolescents - EuroNet-PHL-LP1The first line therapy for childhood nodular lymphocyte-predominant Hodgkin’s lymphoma shall be further optimised to avoid over-treatment and decrease long-term complications.EUCTR2007-004092-19-CZMartin Luther University of Halle/Wittenberg250
进行中（未招募）
1 期
Evaluation of the therapy of Hodgkin’s Lymphoma in Children and AdolescentsEUCTR2007-004092-19-DEMartin Luther University of Halle/Wittenberg200
进行中（未招募）
1 期
EuroNet-Paediatric Hodgkin’s Lymphoma Group First international Inter-Group Studyfor nodular lymphocyte-predominant Hodgkin’s Lymphoma in Children and Adolescents - EuroNet-PHL-LP1The first line therapy for childhood nodular lymphocyte-predominant Hodgkin’s lymphoma shall be further optimised to avoid over-treatment and decrease long-term complications.EUCTR2007-004092-19-ATMartin Luther University of Halle/Wittenberg250
进行中（未招募）
1 期
EuroNet-Paediatric Hodgkin’s Lymphoma Group First international Inter-Group Studyfor classical Hodgkin’s Lymphoma in Children and Adolescents - EuroNet-PHL-C1EUCTR2006-000995-33-SEMartin-Luther-University Halle-Wittenberg1,200
进行中（未招募）
1 期
EuroNet-Paediatric Hodgkin’s Lymphoma Group First international Inter-Group Studyfor classical Hodgkin’s Lymphoma in Children and Adolescents - EuroNet-PHL-C11st and 2nd line therapy for childhood Hodgkin’s lymphoma shall be further optimised to avoid over-treatment and decrease long-term complications.MedDRA version: 14.1Level: HLGTClassification code 10025319Term: Lymphomas Hodgkin's diseaseSystem Organ Class: 10005329 - Blood and lymphatic system disordersEUCTR2006-000995-33-BEMartin-Luther-University Halle-Wittenberg1,200